The global AI-optimized bioprocessing market size was valued at USD 841.60 million in 2024 and is expected to reach USD 5,877.42 million by 2032, at a CAGR of 27.50% during the forecast period
The market growth for AI-optimized bioprocessing is largely fueled by the increasing complexity and scale of biopharmaceutical manufacturing, requiring enhanced efficiency, yield, and consistent product quality. The escalating demand for advanced biologics, including cell and gene therapies, further drives the adoption of intelligent solutions to overcome traditional bioprocessing bottlenecks
Furthermore, rising pressure to reduce manufacturing costs and accelerate time-to-market for novel biotherapeutics is establishing AI-optimized bioprocessing as essential tools for both developers and manufacturers. The shift towards Industry 4.0 principles in biomanufacturing, emphasizing data-driven decision-making, predictive capabilities, and reduced human error, is also contributing to market expansion